There is tentative evidence aripiprazole may be useful in schizophrenia; however, definitive conclusions are difficult to draw as there was a high rate of attrition during trials and there is a lack of outcome data regarding general functioning, behavior, mortality, economic outcomes, or cognitive functioning. It is similar to other typical and atypical antipsychotics with respect to benefit. Compared to typical antipsychotics, there is less extrapyramidal side effects, but higher rates of dizziness. With respect to other atypicals, it is difficult to determine differences in adverse effects as data quality is poor. The efficacy and tolerability of aripiprazole was in the middle range of 15 antipsychotics for efficacy, but had superior tolerability when compared to the other antipsychotic drugs (4th lowest SMD for weight gain, 5th lowest OR for extrapyramidal symptoms, lowest SMD for prolactin elevation, 2nd lowest OR for QTc prolongation, 5th lowest OR for sedation).
When used by itself for bipolar disorder, aripiprazole does not appear to improve symptoms of depression, although it may be useful in preventing mania. Thus, it is often used in combination with an additional mood stabilizer; however, co-administration with a mood stabilizer increases the risk of extrapyramidal side effects.
Aripiprazole is an effective adjunct treatment for major depressive disorder. However, there is a greater rate of side effects as an adjunctive therapy (such as weight gain and akathisia). Aripiprazole is the most efficacious antipsychotic to alleviate symptoms of treatment-resistant major depressive disorder (although not significantly). Likewise, in a few earlier meta-analyses, similar results were obtained. Aripiprazole may pharmacokinetically interact with some antidepressants, especially SSRIs. There are significant interactions with fluoxetine and paroxetine and lesser interactions with sertraline, escitalopram, citalopram and fluvoxamine, which inhibit CYP2D6, for which aripiprazole is a substrate.
Short-term data (8 weeks) shows reduced irritability, hyperactivity, and stereotypy. Adverse effects included weight gain, sleepiness, drooling and tremors. Long-term outcomes are not clear.
Sudden unexplained death has been reported, however the frequency is unknown.
Common in children
Uncontrolled movement such as restlessness, tremor muscle stiffness 
Aripiprazole should be discontinued gradually, with careful consideration from the prescribing doctor, to avoid withdrawal symptoms or relapse.
The British National Formulary recommends a gradual withdrawal when discontinuing anti-psychotic treatment to avoid acute withdrawal syndrome or rapid relapse. Due to compensatory changes at dopamine, serotonin, adrenergic and histamine receptor sites in the central nervous system, withdrawal symptoms can occur during abrupt or over-rapid reduction in dosage. Withdrawal symptoms reported to occur after discontinuation of antipsychotics include nausea, emesis, lightheadedness, diaphoresis, dyskinesia, orthostatic hypotension, tachycardia, rhabdomyolysis, nervousness, dizziness, headache, excessive non-stop crying, and anxiety. Some have argued that additional somatic and psychiatric symptoms associated with dopaminergic super-sensitivity, including dyskinesia and acute psychosis, are common features of withdrawal in individuals treated with neuroleptics. This has led some to suggest that the withdrawal process might itself be schizo-mimetic, producing schizophrenia-like symptoms even in previously healthy patients, indicating a possible pharmacological origin of mental illness in a yet unknown percentage of patients currently and previously treated with antipsychotics. This question is unresolved, and remains a highly controversial issue among professionals in the medical and mental health communities, as well the public.
Children or adults who ingested acute overdoses have usually manifested central nervous system depression ranging from mild sedation to coma; serum concentrations of aripiprazole and dehydroaripiprazole in these patients were elevated by up to 3-4 fold over normal therapeutic levels, yet to date no deaths have been recorded.
Aripiprazole is a substrate of CYP2D6 and CYP3A4. Coadministration with medications that inhibit (e.g. paroxetine, fluoxetine) or induce (e.g. carbamazepine) these metabolic enzymes are known to increase and decrease, respectively, plasma levels of aripiprazole. As such, anyone taking aripiprazole should be aware that their dosage of aripiprazole may need to be decreased.
Aripiprazole may change the subjective effects of alcohol. One study found that aripiprazole increased the sedative effect and reduced the sense of euphoria normally associated with alcohol consumption. However, another alcohol study found that there was no difference in subjective effect between a placebo group and a group taking aripiprazole.
For the purpose of D2 blockage, aripiprazole, a partial agonist on D2 receptor site, should not be used with a full antagonist.[medical citation needed]
Precautions should be taken in patients with an established diagnosis of diabetes mellitus who are started on atypical antipsychotics along with other medications that affect blood sugar levels and should be monitored regularly for worsening of glucose control. The liquid form (oral solution) of this medication may contain up to 15 grams of sugar per dose. Patients with risk factors for diabetes mellitus (eg, obesity, family history of diabetes) who are starting treatment with atypical antipsychotics should undergo fasting blood glucose testing at the beginning of treatment and periodically during treatment. Any patient treated with atypical antipsychotics should be monitored for symptoms of hyperglycemia including polydipsia (excessive thirst), polyuria (excessive urination), polyphagia (increased appetite), and weakness.
D2 and D3 receptor occupancy levels are high, with average levels ranging between ~71% at 2 mg/day to ~96% at 40 mg/day. Most atypical antipsychotics bind preferentially to extrastriatal receptors, but aripiprazole appears to be less preferential in this regard, as binding rates are high throughout the brain.
Recently, it has been demonstrated that in 5-HT7 receptor knockout mice, aripiprazole does not reduce immobility time in the forced swim test (FST), and actually increases it. This implicates 5-HT7 antagonism as playing a major role in aripiprazole's antidepressant effects, similarly to amisulpride. Note, however, humans possess a splice variant not found in other mammals (the "d" isoform), while mice possess one not found in humans (the "c"). The significantly altered c-terminus observed in 5-HT7(d) results in a similar binding affinity to the other forms of this receptor, however, the "c" variant found in other mammals differs in affinity. This difference in expression means the receptor's function in modulating thalamic and hypothalamic output, and corresponding effect on fatigue perception and alertness may not be homologous in mice and humans.
Aripiprazole displays linear kinetics and has an elimination half-life of approximately 75 hours. Steady-state plasma concentrations are achieved in about 14 days. Cmax (maximum plasma concentration) is achieved 3–5 hours after oral dosing. Bioavailability of the oral tablets is about 90% and the drug undergoes extensive hepatic metabolization (dehydrogenation, hydroxylation, and N-dealkylation), principally by the enzymes CYP2D6 and CYP3A4. Its only known active metabolite is dehydro-aripiprazole, which typically accumulates to approximately 40% of the aripiprazole concentration. The parenteral drug is excreted only in traces, and its metabolites, active or not, are excreted via feces and urine. When dosed daily, brain concentrations of aripiprazole will increase for a period of 10–14 days, before reaching stable constant levels.
Society and culture
In the United States, the FDA has approved aripiprazole for the treatment of schizophrenia in adults and adolescents (aged 13–17), of manic and mixed episodes associated with Bipolar I (One) Disorder with or without psychotic features in adults, children and adolescents (aged 10–17), of irritability associated with autism in pediatric patients (aged 6–17), and of depression when used along with antidepressants in adults.
Aripiprazole is also used off-label for schizophrenia in children (aged 10–12), and to treat dementia-related psychosis in geriatric patients, though Bristol-Myers Squibb was penalized for promoting such uses in the United States.
Aripiprazole has been approved by the FDA for the treatment of acute manic and mixed episodes, in both pediatric patients aged 10–17 and in adults.
In 2007, aripiprazole was approved by the FDA for the treatment of unipolar depression when used adjunctively with an antidepressant medication. It has not been FDA-approved for use as monotherapy in unipolar depression.
Aripiprazole can be synthesized beginning with a dichloroaniline and bis(2-chloroethyl)amine:
Perhaps owing to its mechanism of action relating to dopamine receptors, there is some evidence to suggest that aripiprazole blocks cocaine-seeking behavior in animal models without significantly affecting other rewarding behaviors (such as food self-administration). The book Addiction Medicine mentions studies that suggest aripiprazole would be counter-therapeutic as treatment for methamphetamine dependency because it increased methamphetamine's stimulant and euphoric effects, and increased the baseline level of desire for methamphetamine.
^Khanna, P; Komossa, K; Rummel-Kluge, C; Hunger, H; Schwarz, S; El-Sayeh, HG; Leucht, S (Feb 28, 2013). "Aripiprazole versus other atypical antipsychotics for schizophrenia.". Cochrane database of systematic reviews (Online)2: CD006569. doi:10.1002/14651858.CD006569.pub4. PMID23450570.
^ abcLeucht S, Cipriani A, Spineli L, Mavridis D, Örey D, Richter F, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. The Lancet [Internet]. 2013 Jun 27 [cited 2013 Sep 17];382(9896) 951–62. Available from: http://www.sciencedirect.com/science/article/pii/S0140673613607333
^De Fruyt, J; Deschepper, E; Audenaert, K; Constant, E; Floris, M; Pitchot, W; Sienaert, P; Souery, D; Claes, S (May 2012). "Second generation antipsychotics in the treatment of bipolar depression: a systematic review and meta-analysis.". Journal of psychopharmacology (Oxford, England)26 (5): 603–17. doi:10.1177/0269881111408461. PMID21940761.
^de Bartolomeis, A; Perugi, G (October 2012). "Combination of aripiprazole with mood stabilizers for the treatment of bipolar disorder: from acute mania to long-term maintenance.". Expert opinion on pharmacotherapy13 (14): 2027–36. doi:10.1517/14656566.2012.719876. PMID22946707.
^Komossa, K; Depping, AM; Gaudchau, A; Kissling, W; Leucht, S (Dec 8, 2010). "Second-generation antipsychotics for major depressive disorder and dysthymia.". Cochrane database of systematic reviews (Online) (12): CD008121. doi:10.1002/14651858.CD008121.pub2. PMID21154393.
^Spielmans, GI; Berman MI; Linardatos E; Rosenlicht NZ; Perry A; Tsai AC (Mar 12, 2013). "Adjunctive atypical antipsychotic treatment for major depressive disorder: a meta-analysis of depression, quality of life, and safety outcomes". Cochrane database of systematic reviews (Online)10 (3): CD008121. doi:10.1371/journal.pmed.1001403. PMID23554581.
^Spielmans GI, Berman MI, Linardatos E, Rosenlicht NZ, Perry A, Tsai AC. Adjunctive Atypical Antipsychotic Treatment for Major Depressive Disorder: A Meta-Analysis of Depression, Quality of Life, and Safety Outcomes. PLoS Med [Internet]. 2013 Mar [cited 2013 Sep 17];10(3). Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3595214/
^Nelson MD, Papakostas MD. Atypical Antipsychotic Augmentation in Major Depressive Disorder: A Meta-Analysis of Placebo-Controlled Randomized Trials. Am J Psychiatry [Internet]. 2009 Sep 1 [cited 2013 Sep 17];166(9) 980–91. Available from: http://dx.doi.org/10.1176/appi.ajp.2009.09030312
^Zaidi SH, Faruqui RA (January 2008). "Aripiprazole is associated with early onset of Tardive Dyskinesia like presentation in a patient with ABI and psychosis". Brain Inj22 (1): 99–102. doi:10.1080/02699050701822493. PMID18183513.
^Maytal G, Ostacher M, Stern TA (June 2006). "Aripiprazole-related tardive dyskinesia". CNS Spectr11 (6): 435–9. PMID16816781.
^Group, BMJ, ed. (March 2009). "4.2.1". British National Formulary (57 ed.). United Kingdom: Royal Pharmaceutical Society of Great Britain. p. 192. ISBN978-0-85369-845-6. "Withdrawal of antipsychotic drugs after long-term therapy should always be gradual and closely monitored to avoid the risk of acute withdrawal syndromes or rapid relapse."
^Starrenburga, F.C.J.; J.P.A.M. Bogersb (April 2009). "How can antipsychotics cause diabetes mellitus? Insights based on receptor-binding profiles, humoral factors and transporter proteins". European Psychiatry24 (3): 164–170. doi:10.1016/j.eurpsy.2009.01.001. PMID19285836.
^Nguyen CT, Rosen JA, Bota RG. Aripiprazole Partial Agonism at 5-HT2C: A Comparison of Weight Gain Associated With Aripiprazole Adjunctive to Antidepressants With High Versus Low Serotonergic Activities. Prim Care Companion CNS Disord [Internet]. 2012 [cited 2013 Jul 22];14(5). Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3583771/
^Burstein ES, Ma J, Wong S, Gao Y, Pham E, Knapp AE, et al. Intrinsic Efficacy of Antipsychotics at Human D2, D3, and D4 Dopamine Receptors: Identification of the Clozapine Metabolite N-Desmethylclozapine as a D2/D3 Partial Agonist. J Pharmacol Exp Ther [Internet]. 2005 Dec 1 [cited 2013 Jul 22];315(3) 1278–87. Available from: http://jpet.aspetjournals.org/content/315/3/1278.full.pdf
^Lawler CP et al. (1999). "Interactions of the novel antipsychotic aripiprazole (OPC-14597) with dopamine and serotonin receptor subtypes". Neuropsychopharmacology20 (6): 612–27. doi:10.1016/S0893-133X(98)00099-2. PMID10327430.
^Burstein ES, Ma J, Wong S, Gao Y, Pham E, Knapp AE, Nash NR, Olsson R, Davis RE, Hacksell U, Weiner DM, Brann MR (December 2005). "Intrinsic Efficacy of Antipsychotics at Human D2, D3, and D4 Dopamine Receptors: Identification of the Clozapine Metabolite N-Desmethylclozapine as a D2/D3 Partial Agonist". J Pharmacol Exp Ther315 (3): 1278–87. doi:10.1124/jpet.105.092155. PMID16135699.
^Shapiro, DA et al. (2003). "Aripiprazole, A Novel Atypical Antipsychotic Drug with a Unique and Robust Pharmacology". Neuropsychopharmacology28 (8): 1400–1411. doi:10.1038/sj.npp.1300203. PMID12784105.
^Zhang JY, Kowal DM, Nawoschik SP, Lou Z, Dunlop J (February 2006). "Distinct functional profiles of aripiprazole and olanzapine at RNA edited human 5-HT2C receptor isoforms". Biochem Pharmacol71 (4): 521–9. doi:10.1016/j.bcp.2005.11.007. PMID16336943.
^Kegeles, LS et al. (2008). "Dose–Occupancy Study of Striatal and Extrastriatal Dopamine D2 Receptors by Aripiprazole in Schizophrenia with PET and [18F]Fallypride". Neuropsychopharmacology33 (13): 3111–3125. doi:10.1038/npp.2008.33. PMID18418366.
^Yokoi F, Gründer G, Biziere K, Stephane M, Dogan AS, Dannals RF, Ravert H, Suri A, Bramer S, Wong DF (August 2002). "Dopamine D2 and D3 receptor occupancy in normal humans treated with the antipsychotic drug aripiprazole (OPC 14597): a study using positron emission tomography and [11C]raclopride". Neuropsychopharmacology27 (2): 248–59. doi:10.1016/S0893-133X(02)00304-4. PMID12093598.